Introduction {#s1}
============

Gaseous microemboli (GME) may occur during several invasive procedures and despite excellent surgical techniques and highest operative standards, the clinical intervention with the highest risk of GME formation is cardiac surgery with the use of extracorporeal circulation.^[@B1],[@B2])^ GME are associated with postoperative neurocognitive dysfunction and negative clinical outcome, which have been classified into two subgroups by the "American College of Cardiology," respectively, the American Heart Association guidelines. Group 1 patients suffer from a major focal neurologic deficit, going ahead with stupor or coma, whereas the group 2 dysfunctions include confusion, memory deficits, seizures, etc.^[@B3],[@B4])^ Overall, the clinical outcome after suffering from GME during cardiac surgery is determined by size and location of the GME, as well as by general status and comorbidities of patients. Massive GME are usually fatal, both in the venous and arterial circulation.^[@B5])^ If large gaseous embolisms migrate into the pulmonary circulation and obstruct the right ventricular outflow, this pulmonary embolism increases resistance in the right ventricle and leads to reduction of left ventricular preload.^[@B1])^ Although GME could concern any organ, occlusion of cerebral and cardiac circulation are especially harmful as these systems are highly vulnerable to ischemia.^[@B3])^ In addition, GME interact with blood cells (leucocytes and platelets) and initiate an inflammatory response. The inflammatory cascade then itself causes an exacerbation of the cerebral injury.^[@B6])^ Studies showed that the greater the number of GME, the worse the cognitive outcome for patients after cardiac surgery.^[@B7])^ Similar applies to the rate of perfusionists' interventions: an increased number of interventions during extracorporeal circulation leads to an increased number of GME, which has a negative impact on the postoperative course after cardiac surgery.^[@B7])^ Despite the fact that recent membrane oxygenators can eliminate large amounts of potential GME from the extracorporeal circuit via the venous reservoir, the oxygenator- and the arterial line filter,^[@B8])^ still 30% of patients even experience long-term complications.^[@B6])^

Previous studies showed that regarding GME-prevention common oxygenators have significantly different capacities to reduce the amount and volume of GMEs.^[@B6],[@B9],[@B10])^ However, until now, no study investigated whether the type of oxygenator has impact on clinical outcome after cardiac surgery. We therefore performed a respective analysis with the hypothesis that the type of oxygenator affects the clinical outcome after cardiac surgery with extracorporeal circulation. The aim of our study was to test this hypothesis by comparing three common oxygenator designs retrospectively with special focus on perioperative outcome after cardiac surgery.

Materials and Methods {#s2}
=====================

Study design and patients {#s2-1}
-------------------------

We performed a retrospective analysis of patients that underwent cardiac surgery between May and June 2016 at the University Hospital of the RWTH Aachen (Germany). In all, 55 patients undergoing elective cardiac surgery with the use extracorporeal circulation were consecutively assigned to be perfused with three different oxygenator models with integrated arterial filter: the HiliteAF 7000 (Medos Medizintechnik AG, Stolberg Rhineland, Germany), the Fusion Affinity (Medtronic Minneapolis, MN, USA), or the Synthesis (Sorin Group/LivaNova, Mirandola, Italy). All three oxygenators are comparable with regard to their cylindrical hollow fiber bundles, the same fiber material, and similar maximum volume flows; however, differences in the design specifications of the three models are presented in **[Table 1](#table1){ref-type="table"}**. We excluded patients with preoperative neurologic incidents, emergency, or re-do procedures.

###### Specifications of study oxygenators and patient characteristics

                                                          Medos Hilite (n = 19)                                                                                                                 Medtronic (n = 18)                                                                                                                Sorin Synthesis (n = 18)
  ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------
  Specifications of oxygenators                                                                                                                                                                                                                                                                                                    
   Blood flow rate (max)                                  7 L/min                                                                                                                               7 L/min                                                                                                                           8 L/min
   Filling volume                                         320 mL                                                                                                                                260 mL                                                                                                                            430 mL
   Gas exchanger material                                 Polypropylene                                                                                                                         Polypropylene                                                                                                                     Polypropylene
   Gas exchanger surface                                  1.9 m^2^                                                                                                                              2.5 m^2^                                                                                                                          2 m^2^
   Heat exchanger material                                Polyethylene                                                                                                                          Polyethylene terephthalate (PET)                                                                                                  Stainless steel
   Heat exchanger surface                                 0.45 m^2^                                                                                                                             0.4 m^2^                                                                                                                          0.14 m^2^
   Pore size arterial filter                              40 µm                                                                                                                                 25 µm                                                                                                                             40 µm
   System coating                                         x.eed coating                                                                                                                         Balance Biosurface                                                                                                                Phosphorylcholine coating
   Pressure loss at max. blood flow                       Approx. 190 mmHg                                                                                                                      Approx. 160 mmHg                                                                                                                  Approx. 260 mmHg
   Heat exchanger performance factor at max. blood flow   Approx. 55%                                                                                                                           Approx. 50%                                                                                                                       Approx. 35%
   Flow guidance                                          Substantially longitudinally directed, initially along the heat exchanger fibers, then longitudinally along the gas exchange fibers   First through the heat exchanger, which is installed below the gas exchanger. In the fiber bundle (separate housing) cross-flow   First along the heat exchange fibers. Then "wavy" through the fiber bundle. Filter separately in a chamber placed around the gas exchange bundle
  Patient characteristics                                                                                                                                                                                                                                                                                                          
   Age                                                    63.74 ± 7.25                                                                                                                          66.28 ± 9.5                                                                                                                       68.89 ± 8.18
   Sex (male/female)                                      19/0                                                                                                                                  12/6                                                                                                                              13/5
   Pre-existing conditions                                                                                                                                                                                                                                                                                                         
   Diabetes mellitus Type 2                               7                                                                                                                                     2                                                                                                                                 6
   Arterial hypertension                                  14                                                                                                                                    13                                                                                                                                12
   Anti-coagulation therapy                                                                                                                                                                                                                                                                                                        
    Aspirin                                               15                                                                                                                                    15                                                                                                                                8
    Marcumar                                              1                                                                                                                                     2                                                                                                                                 4
    Other                                                 5                                                                                                                                     0                                                                                                                                 0
   Adiposities per magna (BMI \>30)                       8                                                                                                                                     8                                                                                                                                 4
   Current tobacco use                                    10                                                                                                                                    10                                                                                                                                5
   Cardiac surgery                                                                                                                                                                                                                                                                                                                 
    CABG surgery                                          15                                                                                                                                    13                                                                                                                                13
    Valve surgery                                         4                                                                                                                                     5                                                                                                                                 5
    CPB time (min)                                        118.32 ± 37.70                                                                                                                        113.17 ± 28.72                                                                                                                    126.50 ± 61.28
    Aortic cross-clamp time (min)                         74.63 ± 28.22                                                                                                                         70.56 ± 20                                                                                                                        73.28 ± 29.72
    Reperfusion time (min)                                31.89 ± 10.43                                                                                                                         36.31 ± 11.20                                                                                                                     38.61 ± 8.18
    Minimal blood temperature (°C)                        30.21 ± 2.31                                                                                                                          29.88 ± 1.93                                                                                                                      29.61 ± 2.65

CABG: coronary artery bypass grafting; CPB: cardiopulmonary bypass; BMI: body mass index

Operative management {#s2-2}
--------------------

Patients received perioperative care according to institutional standards. Standard cardiovascular and respiratory monitoring such as heart rate, peripheral oxygen saturation, and non-invasive and invasive arterial blood pressure were continuously monitored.

Surgical management consisted of a full median sternotomy and therapeutic heparinization to an activated clotting time (ACT) \>400 sec, followed by the establishment of extracorporeal circulation with arterial inflow through the ascending aorta and venous drainage through a single two-stage right atrium cannula. Myocardial protection consisted of mild to moderate hypothermia (32--28°C) and cold antegrade crystalloid cardioplegic solution (CustodiolTM, Koehler Chemie, Alsbach-Haehnlein, Germany).

Extracorporeal circulation {#s2-3}
--------------------------

All included patients underwent cardiac surgery with a conventional cardiopulmonary bypass (CPB) circuit (Stockert s5, Sorin Group Germany, Munich, Germany). After cross-clamping, cardiac arrest was induced by antegrade infusion of cold crystalloid cardioplegic solution (CustodiolTM, KoehlerChemie). Extracorporeal circulation was performed with a non-pulsatile pump flow of 2.2 L min^−1^ m^−2^.

Gaseous emboli counter {#s2-4}
----------------------

GME were measured in real time using a two-channel ultrasound bubble counter BCC200 (GAMPT, Merseburg, Germany). GME ranging from 10 to 500 µm were counted and classified as "over range" higher than 500 µm. GME were detected and measured cumulatively during the overall extracorporeal circulation time.

Postoperative clinical evaluation {#s2-5}
---------------------------------

Postoperative clinical endpoints included duration of invasive mechanical ventilation on intensive care unit (ICU) in hours, duration of non-invasive mechanical ventilation on ICU in hours, diagnoses of delirium during hospital stay, as assessed by the confusion assessment method for the ICU (CAM-ICU). Furthermore, diagnosis of stroke during hospital stay (defined as any new, temporary or permanent, focal or global neurologic deficit evaluated according to the National Institutes of Health Stroke Scale, with stroke defined as a score of ≥4 points on a scale of 0 to 42, with higher scores indicating greater severity). Acute renal failure during hospital stay was defined as followed: Increased serum creatinine level: ≥0.3 mg/dL compared to Baseline (BL) within 48 hours, or increased serum creatinine level by a factor of ≥1.5 compared to BL within 7 days, or decreased urine output of ≤0.5 mL kg^−1^ h^−1^ for minimum 6 hours. Myocardial infarction during hospital stay was referred to as increase in biomarkers (e.g., troponin), values more than five times the 99th percentile of the normal reference range plus one or more of the following: new pathologic Q waves or new left bundle-branch block within the first 72 hours after surgery, standard clinical criteria for myocardial infarction from 72 hours onward, a new finding of ischemia by echocardiography or angiography.

Statistical analysis {#s2-6}
--------------------

All data were statistically analyzed using a commercially available software package (GraphPad Prism 6.0, Graphpad Software Inc., San Diego, CA, USA). All data were tested for normal distribution with the Shapiro--Wilk's test. Normally distributed data were compared using one-way analysis of variance (ANOVA and for the adverse events in outcome (delirium, stroke, myocardial infarction, acute renal injury) using a two-way repeatedmeasures ANOVA). If the group effect was significant, a Tukey post-hoc test was used for pairwise comparisons between all groups. In case of non-normal distribution, a Kruskal--Wallis test followed by a Dunn's post-hoc test was used. In all cases, a level of p \<0.05 was considered as statistically significant.

Results {#s3}
=======

Patient characteristics {#s3-1}
-----------------------

Demographic and surgical data did not differ significantly between the three groups; details are presented in **[Table 1](#table1){ref-type="table"}**. Additionally, the average amount of heparin per kg bodyweight during surgery was equal for all the groups, without significant differences (Medos Hilite n = 19: 438 ± 111 IU/kg, Medtronic n = 18: 479 ± 120 IU/kg, Sorin Synthesis n = 18: 495 ± 167 IU/kg). No mortality was observed in the Medos Hilite, and the Sorin Synthesis group, one patient from the Medtronic fusion group died during the postoperative course on ICU; all other patients were discharged from hospital without neurologic complications.

Number and volume of GME reduction {#s3-2}
----------------------------------

In **[Fig. 1](#F1){ref-type="fig"}** and **[Table 2](#table2){ref-type="table"}**, the number and volume reduction rates of the three oxygenators are presented. All three oxygenators had different rates in number and volume GME reduction. The Fusion Affinity had the lowest arterial GME volume (1.81 µL ± 0.23 µL), which was statistically significant compared to the Synthesis (3.37 µL ± 0.71 µL, p = 0.014). However, the Synthesis had lower absolute numbers at the venous GME count (31771 µL ± 6579 µL) versus the Fusion Affinity (49304 µL ± 8196 µL). No significant differences were shown between the HiliteAF 7000 and the Fusion Affinity or the HiliteAF 7000 and the Synthesis.

![Absolute counts (Panel **A**) and volumes (Panel **B**) of GMEs detected in inlet line and absolute counts (Panel **C**) and volumes (Panel **D**) of outlet line of the used oxygenators. White bar: Interventional group treated with the Medos HiliteAF oxygenator. Black bar: Interventional group treated with the Medtronic oxygenator; Squared bar: Interventional group treated with the Sorin Synthesis oxygenator; Values are displayed as means ± SD. All data presented as total GME counted during the operative procedure. GME: gaseous microemboli; SD: standard deviation](atcs-24-230-g001){#F1}

###### Volume and number of GME entering (arterial) and leaving (venous) the oxygenator + clinical outcome after cardiac surgery

  ---------------------------------------------------------------------------------------------------------------------------------------
                                                     Medos Hilite\    Medtronic\        Sorin Synthesis\   p value
                                                     (n = 19)         (n = 18)          (n = 18)           
  -------------------------------------------------- ---------------- ----------------- ------------------ ------------------------------
  Venous GME volume (µL)                             17.84 ± 14.28    18.82 ± 13.27     25.08 ± 17.26      0.3345

  Arterial GME volume (µL)                           2.39 ± 0.48      1.81 ± 0.23\*     3.37 ± 0.71        \*0.014 Fusion vs. Synthesis

  Venous GME count                                   56841 ± 9466     49304 ± 8196      31771 ± 6579       0.122

  Arterial GME count                                 9753 ± 5042      10512 ± 1366      9744 ± 1869        0.9173

  Duration invasive mechanical ventilation (hours)   65.74 ± 148.95   115.79 ± 247.80   59.09 ± 133.86     0.5990

  Duration non-invasive\                             2.75 ± 4.43      3.5 ± 4.79        2.75 ± 5.34        0.8661
  mechanical ventilation (hours)                                                                           

  Delirium                                           3                5                 2                  0.633

  Stroke                                             2                1                 2                  1.0

  Acute renal failure                                4                7                 3                  0.525

  New myocardial infarction                          1                0                 0                  1.0
  ---------------------------------------------------------------------------------------------------------------------------------------

Data are reported as mean ± standard deviation (SD). GME: gaseous microemboli

Perioperative outcome after cardiac surgery {#s3-3}
-------------------------------------------

In all three groups, we observed the usual rate of postoperative complications after cardiac surgery. With regard to invasive and non-invasive mechanical ventilation, we found no statistically significant difference between all three groups. The incidence of delirium, stroke, acute renal failure, or new myocardial infarction did not differ between the three groups (**[Table 2](#table2){ref-type="table"}** and **[Fig. 2](#F2){ref-type="fig"}**). Regarding the severity of stroke, in only one out of five stroke events reported in this study, the manifestation of neurocognitive disorders was documented. The four other cases remained without impairment of the neuronal function. Thus, in total for one patient out of 55, we could prove severe stroke-related disorders.

![Comparison of absolute counts of adverse events between the used oxygenators. (Panel **A**: Delirium; Panel **B**: Stroke; Panel **C**: Myocardial infarction; Panel **D**: Acute kidney injury). White bar: Interventional group treated with the Medos HiliteAF oxygenator. Black bar: Interventional group treated with the Medtronic oxygenator; Squared bar: Interventional group treated with the Sorin Synthesis oxygenator; Values are displayed as means ± SD. All data presented as total number of adverse events counted during the postoperative course on ICU. ICU: intensive care unit; SD: standard deviation](atcs-24-230-g002){#F2}

As shown in **[Table 3](#table3){ref-type="table"}**, only one of the five postoperative stroke patients had a history of cerebrovascular disorder prior to the surgery, and the same patient showed a carotid stenosis at the preoperative tests. Furthermore, in only one of the stroke patients preoperative and postoperative atrial fibrillation was reported, whereas in total three out of five stroke patients showed only postoperative atrial fibrillation.

###### Preoperative and postoperative diagnosis of potential risk factors for stroke after cardiac surgery

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stroke patient (no.)   "Preoperative atrial fibrillation"\   "Postoperative atrial fibrillation"\   "History of cerebrovascular disorder prior to surgery"\   "Carotid stenosis at the preoperative test"\
                         (1 = yes/0 = no)                      (1 = yes/0 = no)                       (1 = yes/0 = no)                                          (1 = yes/0 = no)
  ---------------------- ------------------------------------- -------------------------------------- --------------------------------------------------------- ----------------------------------------------
  1                      0                                     1                                      0                                                         0

  2                      1                                     1                                      0                                                         0

  3                      0                                     0                                      0                                                         0

  4                      0                                     1                                      0                                                         0

  5                      0                                     0                                      1                                                         1

  Sum out of five        1                                     3                                      1                                                         1
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion {#s4}
==========

In this study, the impact of the oxygenator-type on clinical outcome after cardiac surgery was investigated and the air-handling capacity of three oxygenators is described. The results show that although all three oxygenators differ in terms of structural specifications and have different rates of number and volume GME reduction, only the Fusion Affinity compared to the Synthesis had a statistically significant lower arterial GME volume. However, with regard to clinical outcome after cardiac surgery (duration of invasive and non-invasive mechanical ventilation, incidence of delirium, stroke, acute renal failure, or new myocardial infarction), we found no differences between the three groups. From these results, it is safe to conclude that recent oxygenators feature bubble traps and arterial filters, which certainly remove bubbles of critical size (\>500 µm) and volume (\>120 µL),^[@B11])^ as the volumes of detected GME ranged from 17.8 to 25.1 µL in the venous circuit and from 1.8 to 3.3 µL in the arterial circuit.

These results are underlined by data from experimental animal studies, which showed that even 120 µL of air reaching the middle cerebral arteries (MCA) do not cause cerebral injury.^[@B12])^ Interestingly, clinical trials support our findings, using transcranial Doppler technology (TCD) in 10 patients.^[@B11])^ Chung and colleagues found that although if the amount of bubbles, respectively, microembolic events in the arterial system during surgery is excessively high (\>18 k), the majority of the bubbles is too small to be harmful.^[@B11])^ In comparison, the amount of microembolic events in our study was \~9 k. Thus, clinical outcome, with regard to delirium, stroke, acute renal failure, and new myocardial infarction during the perioperative course, is not related to the GME formation during cardiac surgery with extracorporeal circulation. Nevertheless, in comparison to the reported incidence of stroke during CPB surgery of 1.3--3.6%,^[@B13])^ the occurrence of stroke in our study was 9%, independent from the group. Especially for patients undergoing coronary artery bypass grafting, the incidence for stroke is reported up to 5%,^[@B14])^ often related to a history of stroke for the patients, or arthrosclerosis.^[@B15])^

Other experimental studies focused exclusively on airhandling properties of current oxygenators. Qiu et al.^[@B12])^ evaluated the Capiox FX05, Wang et al.^[@B16])^ tested Capiox RX25 and the Quadrox-I, both concluded that in a simulated adult CPB circuit the oxygenators performed well. Their findings are in line with the results from a Swedish team,^[@B17])^ who also conclude that incorporated arterial filters reduce GME activity. Our study emphasizes the findings from these experimental studies to clinical results.

It is safe to conclude from our study that all three investigated oxygenators performed well in the setting of cardiac surgery although differences in design and filtration specifications are present. Both the Synthesis and Hilite oxygenator are axial flow devices with high resistances, which deliver higher pressure differentials independently form the flow applied. The Fusion oxygenator has a radial flow membrane with low pressure differentials which are therefore flow-dependent. Only the Hilite and the Synthesis oxygenator have polyester-based filter systems, whereas the Fusion does not provide a polyester-integrated filter.

Our findings of the lowest arterial GME volume found in the Fusion Affinity can be interpreted in the context of its membrane bundle configuration that creates greater resistance to increasing flows than the other oxygenators that use radial flow membrane bundles. This membrane configuration seems to filter GME more efficiently through its polypropylene hollow fibers.

Pressure loss at maximum blood flow varies from 160 mmHg (Fusion Affinity) to 260 mmHg (Synthesis). The gas exchanger surface of the Fusion Affinity (2.5 m^2^) is approximately 25% larger than the gas exchanger surface of the HiliteAF 7000 or the Synthesis. A large surface is often interpreted as an indication of high blood damage (especially platelet activation).^[@B18],[@B19])^ In addition, a large surface indicates inefficient mass transfer.^[@B19])^ This has particular effects on the handling (priming behavior before use, or venting behavior, if air entered the oxygenator during use). Nevertheless, those differences in design specifications had no causal relationship with clinical outcome after cardiac surgery.

Limitations {#s5}
===========

Our study has several limitations; the major limitation is the retrospective nature of our study. Our findings should therefore be confirmed in future prospective randomized trials. It also suffers from the small cohort size and following studies could emphasize our results in larger populations. While this study has demonstrated a number of differences between the three evaluated oxygenators, it cannot be extrapolated to all conventional oxygenator types.

Conclusion {#s6}
==========

We conclude that all three investigated oxygenators effectively eliminated any clinically relevant amount of GME in the setting of cardiac surgery. Despite significant differences in the design specifications, the tested oxygenators also eliminated any relevant GME volumes safely. Thus, no impact of these oxygenators on the clinical outcome after cardiac surgery was detected.
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